Literature DB >> 25443468

Research on expression and importance of p53, p16 and VEGF-C in cervical cancer.

S Cai1, K Han2.   

Abstract

OBJECTIVE: To investigate the expression of p53, p16(INK4A) and VEGF-C proteins in cervical cancer and their clinical importance.
METHODS: The expression of p53, p16(INK4A) and VEGF-C proteins in 125 cases of cervical sections were detected by two-step immunohistochemical EnVision method, and analyzed combined with the clinical and pathological data.
RESULTS: (1) The positive expression rates of p53, p16(INK4A) and VEGF-C proteins were 56.8%, 95.2% and 88%, respectively. (2) The positive expression rate of p53 protein was 75% in lymph node metastasis-positive cases and 48.24% in lymph node metastasis-negative cases (P<0.05). The presence of difference for positive significant p53 in squamous cell carcinoma and adenocarcinoma is intensively large (P<0.01), but its expression is not much influenced by age, degree of differentiation, parametric infiltration, vascular metastasis or clinical staging (P>0.05). (3) The p16(INK4A) expression in squamous cell carcinoma is 95.65%, and it is 93.94% in adenocarcinoma, the differential expression rates bears no statistically significant, but the strong expression of squamous cell carcinoma covers 55.43% of the total number of squamous cell carcinoma, while only 15.15% rates in adenocarcinoma (P<0.01). The p16(INK4A) protein expression was not significantly correlated to age, histological type, degree of differentiation, lymph node metastasis, parametric infiltration, vascular metastasis or clinical staging (P>0.05). (4) Among the cases of lymph node metastasis, there were 100% of VEGF-C-positive expression and 82.35% of VEGF-C-negative expression, and the difference was significant (P<0.05). Among the cases of vasculature-positive samples of cervical cancer, there were 98.4% of VEGF-C-positive expression; while among the vasculature-negative samples of cervical cancer, there were 76.27% of VEGF-C-positive expression; the difference was significant (P<0.01). VEGF-C protein expression was not significantly correlated to age, histological type, degree of differentiation, parametric infiltration or clinical staging (P>0.05).
CONCLUSIONS: The expression of some immune enzymes in cervical cancer has a reference value for early diagnosis and prognosis of cervical cancer, and has a certain guiding significance for development of the treatment program. However, a larger sample is needed for supporting the research of its significance.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cancer du col de l’utérus; Cervical cancer; Enzyme immune; Ganglion; Immune enzyme; Immunohistochemistry; Immunohistochimie; Lymph node metastases; Métastase; VEGF-C; p16(INK4A); p53

Mesh:

Substances:

Year:  2014        PMID: 25443468     DOI: 10.1016/j.jgyn.2014.07.012

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  4 in total

Review 1.  The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy.

Authors:  Sylvia Annabel Dass; Rehasri Selva Rajan; Gee Jun Tye; Venugopal Balakrishnan
Journal:  Hum Vaccin Immunother       Date:  2021-05-14       Impact factor: 3.452

2.  OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia.

Authors:  Rui Tong; Qing Yang; Chunyan Wang; Fangfang Bi; Bing Jiang
Journal:  Oncol Lett       Date:  2017-03-13       Impact factor: 2.967

3.  Expression of p53 and its mechanism in prostate cancer.

Authors:  Jiukai Wan; Jun Zhang; Junqiang Zhang
Journal:  Oncol Lett       Date:  2018-05-09       Impact factor: 2.967

4.  Synergistic Action of 1,2-Epoxy-3 (3- (3,4-dimethoxyphenyl)- 4H-1-benzopiyran-4-on) Propane with Doxorubicin and Cisplatin through Increasing of p53, TIMP-3, and MicroRNA-34a in Cervical Cancer Cell Line (HeLa)

Authors:  Lelly Yuniarti; Mustofa Mustofa; Teguh Aryandono; Sofia Mubarika Haryana
Journal:  Asian Pac J Cancer Prev       Date:  2018-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.